This company listing is no longer active
CCXI Aktienübersicht
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.
Schneeflocken-Punktzahl | |
---|---|
Bewertung | 2/6 |
Künftiges Wachstum | 5/6 |
Vergangene Leistung | 0/6 |
Finanzielle Gesundheit | 4/6 |
Dividenden | 0/6 |
ChemoCentryx, Inc. Wettbewerber
Preisentwicklung & Leistung
Historische Aktienkurse | |
---|---|
Aktueller Aktienkurs | US$51.99 |
52-Wochen-Hoch | US$52.00 |
52-Wochen-Tief | US$14.95 |
Beta | 1.23 |
11 Monat Veränderung | 0.41% |
3 Monate Veränderung | 134.51% |
1 Jahr Veränderung | 50.39% |
33 Jahre Veränderung | 558.10% |
5 Jahre Veränderung | 642.71% |
Veränderung seit IPO | 372.64% |
Aktuelle Nachrichten und Updates
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09Recent updates
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09ChemoCentryx: Revisiting The Investment Case
Jun 21ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Jun 06ChemoCentryx: Good Post-Approval Performance, But Needs More Time
Mar 03ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Feb 11Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week
Jan 21Checking In On ChemoCentryx
Dec 15Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?
Oct 09ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way
Sep 29ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
Aug 24Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook
Aug 11ChemoCentryx: CRL Less Likely
Jul 25ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price
Jul 11ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jun 15ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress
Jun 08ChemoCentryx: CRL Likely
May 09ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action
May 07Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate
May 04When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?
Mar 03ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 04ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price
Jan 14Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?
Dec 31Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)
Dec 23ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study
Dec 21Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?
Dec 13Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?
Nov 22ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10Aktionärsrenditen
CCXI | US Biotechs | US Markt | |
---|---|---|---|
7D | 0.1% | 0.06% | 0.1% |
1Y | 50.4% | 9.9% | 24.1% |
Rendite im Vergleich zur Industrie: CCXI exceeded the US Biotechs industry which returned -1.9% over the past year.
Rendite vs. Markt: CCXI exceeded the US Market which returned -19.8% over the past year.
Preisvolatilität
CCXI volatility | |
---|---|
CCXI Average Weekly Movement | 31.3% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.4% |
10% least volatile stocks in US Market | 2.8% |
Stabiler Aktienkurs: CCXI's share price has been volatile over the past 3 months.
Volatilität im Zeitverlauf: CCXI's weekly volatility has increased from 18% to 31% over the past year.
Über das Unternehmen
Gegründet | Mitarbeiter | CEO | Website |
---|---|---|---|
1996 | 178 | n/a | www.chemocentryx.com |
ChemoCentryx, Inc.'s Grundlagenzusammenfassung
CCXI grundlegende Statistiken | |
---|---|
Marktanteil | US$3.74b |
Gewinn(TTM) | -US$133.09m |
Umsatz(TTM) | US$37.28m |
100.3x
Kurs-Umsatz-Verhältnis-28.1x
Kurs-Gewinn-VerhältnisIst CCXI zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
CCXI Gewinn- und Verlustrechnung (TTM) | |
---|---|
Einnahmen | US$37.28m |
Kosten der Einnahmen | US$71.86m |
Bruttogewinn | -US$34.58m |
Sonstige Ausgaben | US$98.51m |
Umsatz | -US$133.09m |
Zuletzt gemeldete Gewinne
Jun 30, 2022
Datum des nächsten Gewinnberichts
k.A.
Gewinn per Aktie (EPS) | -1.85 |
Bruttomarge | -92.76% |
Nettogewinnspanne | -357.01% |
Schulden/Eigenkapital-Verhältnis | 10.5% |
Wie hat sich CCXI auf lange Sicht entwickelt?
Historische Performance und Vergleiche